HIV-1 infection

Active Ingredient: Maraviroc

Indication for Maraviroc

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adults, adolescents and children of 2 years of age, and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable.

For this indication, competent medicine agencies globally authorize below treatments:

300-1200 mg in 2 divided doses daily

Route of admnistration

Oral

Defined daily dose

300 - 1,200 mg

Dosage regimen

From 150 To 600 mg 2 time(s) per day every day

Detailed description

Children from 2 years of age and weighing at least 10 kg

The recommended dose of maraviroc should be based on body weight (kg) and should not exceed the recommended adult dose.

The recommended dose of maraviroc differs depending on interactions with concomitant antiretroviral therapy and other medicinal products.

Many medicines have profound effects on maraviroc exposure due to drug-drug interactions. The corresponding paediatric dose can then be obtained from the table below.

Recommended dosing regimen in children aged 2 years and above and weighing at least 10 kg:

Adult dosage*Concomitant MedicationsDose of maraviroc in children based on weight
10 to less than 20 kg20 to less than 30 kg30 to less than 40 kgat least 40 kg
150 mg twice dailymaraviroc with products that are potent CYP3A inhibitors (with or without a CYP3A inducer)50 mg twice daily75 mg twice daily100 mg twice daily150 mg twice daily
300 mg twice dailymaraviroc with products that are not potent CYP3A inhibitors or potent CYP3A inducersData to support these doses are lacking.300 mg twice daily300 mg twice daily
600 mg twice dailymaraviroc with products that are CYP3A inducers (without a potent CYP3A inhibitor)Data to support these doses are lacking and maraviroc is not recommended in children taking concomitant interacting medicinal products that in adults would require a 600 mg twice daily dose.

* Based on drug-drug Interactions

Dosage considerations

Maraviroc can be taken with or without food.

Active ingredient

Maraviroc

Maraviroc is a member of a therapeutic class called CCR5 antagonists. Maraviroc selectively binds to the human chemokine receptor CCR5, preventing CCR5-tropic HIV-1 from entering cells.

Read more about Maraviroc

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.